These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 15261143)

  • 1. The Sema domain of Met is necessary for receptor dimerization and activation.
    Kong-Beltran M; Stamos J; Wickramasinghe D
    Cancer Cell; 2004 Jul; 6(1):75-84. PubMed ID: 15261143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
    Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
    Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noncompetitive inhibition of hepatocyte growth factor-dependent Met signaling by a phage-derived peptide.
    Tam EM; Runyon ST; Santell L; Quan C; Yao X; Kirchhofer D; Skelton NJ; Lazarus RA
    J Mol Biol; 2009 Jan; 385(1):79-90. PubMed ID: 18973760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptor molecule Crk is required for sustained phosphorylation of Grb2-associated binder 1 and hepatocyte growth factor-induced cell motility of human synovial sarcoma cell lines.
    Watanabe T; Tsuda M; Makino Y; Ichihara S; Sawa H; Minami A; Mochizuki N; Nagashima K; Tanaka S
    Mol Cancer Res; 2006 Jul; 4(7):499-510. PubMed ID: 16849525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist.
    Kirchhofer D; Lipari MT; Santell L; Billeci KL; Maun HR; Sandoval WN; Moran P; Ridgway J; Eigenbrot C; Lazarus RA
    Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5306-11. PubMed ID: 17372204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.
    Hov H; Holt RU; Rø TB; Fagerli UM; Hjorth-Hansen H; Baykov V; Christensen JG; Waage A; Sundan A; Børset M
    Clin Cancer Res; 2004 Oct; 10(19):6686-94. PubMed ID: 15475459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists.
    Michieli P; Basilico C; Pennacchietti S; Maffè A; Tamagnone L; Giordano S; Bardelli A; Comoglio PM
    Oncogene; 1999 Sep; 18(37):5221-31. PubMed ID: 10498872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells.
    Ye M; Hu D; Tu L; Zhou X; Lu F; Wen B; Wu W; Lin Y; Zhou Z; Qu J
    Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):497-504. PubMed ID: 18234991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the met receptor in mesothelioma.
    Mukohara T; Civiello G; Davis IJ; Taffaro ML; Christensen J; Fisher DE; Johnson BE; Jänne PA
    Clin Cancer Res; 2005 Nov; 11(22):8122-30. PubMed ID: 16299245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MUC20 suppresses the hepatocyte growth factor-induced Grb2-Ras pathway by binding to a multifunctional docking site of met.
    Higuchi T; Orita T; Katsuya K; Yamasaki Y; Akiyama K; Li H; Yamamoto T; Saito Y; Nakamura M
    Mol Cell Biol; 2004 Sep; 24(17):7456-68. PubMed ID: 15314156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway.
    Tiran Z; Oren A; Hermesh C; Rotman G; Levine Z; Amitai H; Handelsman T; Beiman M; Chen A; Landesman-Milo D; Dassa L; Peres Y; Koifman C; Glezer S; Vidal-Finkelstein R; Bahat K; Pergam T; Israel C; Horev J; Tsarfaty I; Ayalon-Soffer M
    Clin Cancer Res; 2008 Jul; 14(14):4612-21. PubMed ID: 18628476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct interaction of focal adhesion kinase (FAK) with Met is required for FAK to promote hepatocyte growth factor-induced cell invasion.
    Chen SY; Chen HC
    Mol Cell Biol; 2006 Jul; 26(13):5155-67. PubMed ID: 16782899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ets-1 triggers and orchestrates the malignant phenotype of mammary cancer cells within their matrix environment.
    Furlan A; Vercamer C; Desbiens X; Pourtier A
    J Cell Physiol; 2008 Jun; 215(3):782-93. PubMed ID: 18181172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo.
    Martens T; Schmidt NO; Eckerich C; Fillbrandt R; Merchant M; Schwall R; Westphal M; Lamszus K
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6144-52. PubMed ID: 17062691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
    Christensen JG; Burrows J; Salgia R
    Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.
    Merchant M; Ma X; Maun HR; Zheng Z; Peng J; Romero M; Huang A; Yang NY; Nishimura M; Greve J; Santell L; Zhang YW; Su Y; Kaufman DW; Billeci KL; Mai E; Moffat B; Lim A; Duenas ET; Phillips HS; Xiang H; Young JC; Vande Woude GF; Dennis MS; Reilly DE; Schwall RH; Starovasnik MA; Lazarus RA; Yansura DG
    Proc Natl Acad Sci U S A; 2013 Aug; 110(32):E2987-96. PubMed ID: 23882082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy.
    Heideman DA; Overmeer RM; van Beusechem VW; Lamers WH; Hakvoort TB; Snijders PJ; Craanen ME; Offerhaus GJ; Meijer CJ; Gerritsen WR
    Cancer Gene Ther; 2005 Dec; 12(12):954-62. PubMed ID: 15905856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas.
    Hecht M; Papoutsi M; Tran HD; Wilting J; Schweigerer L
    Cancer Res; 2004 Sep; 64(17):6109-18. PubMed ID: 15342394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.